less than 1 minute read

Jüri Reimand collaborated with the Pan-Prostate Cancer Group (PPCG) on a biomarker study of prostate cancer that was published in European Urology. The team characterised rare germline variants in hallmark cancer pathways that are predictive of biochemical recurrence of prostate cancer. PPCG is an international cancer genomics consortium that collects whole-genome sequencing data of thousands of prostate cancers and analyses these data comprehensively for fundamental and translational insights.